Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, a consultant clinical and laboratory hematologist at St. Vincent’s Hospital in East Melbourne, Australia talks about the use of carfilzomib (Kyprolis), dexamethasone, and daratumumab (Darzalex) as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Lenalidomide and bortezomib are often used to treat patients with newly-diagnosed multiple myeloma. However, many patients progress while on these agents or discontinue them due to toxicity. According to Quach, not all jurisdictions are able to afford the higher cost combination of carfilzomib and lenalidomide. Therefore, a more affordable yet equally effective alternative must be found.
The study, which was presented at the 62nd American Society of Hematology Meeting and Exposition, is a collaboration between the Asian Myeloma Network and the Australian Leukemia Myeloma Group.
Novel BTK Degrader BGB-16673 Shows Activity in WM and CLL/SLL
December 10th 2024The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.
Read More
Lisaftoclax Plus Pd Demonstrates Strong Response and Safety in RRMM
December 10th 2024Lisaftoclax, a BCL-2 inhibitor, demonstrated efficacy and tolerability in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma as well as amyloidosis.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
